PLYMOUTH MEETING, Pa. – November 05, 2026 -- INOVIO Pharmaceuticals (Nasdaq: INO) plans to raise capital through an underwritten public offering of its common stock, with all shares sold by the company itself.
Underwriters hold a 30-day option on up to 15% additional shares
INOVIO intends to grant the underwriters a 30-day option to buy additional shares, capped at 15% of the shares sold in the base offering and priced on the same terms. The company has not disclosed the number of shares or the pricing. It said there is no assurance the offering will be completed, or on what size or terms, and that it remains subject to market conditions.
Jefferies and Piper Sandler are acting as joint book-running managers.
Shelf registration took effect on July 10, 2026
The shares are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission on July 2, 2026. The SEC declared it effective on July 10, 2026. The offering will be made only by a written prospectus and prospectus supplement. INOVIO will file a preliminary prospectus supplement with the SEC.
The company points investors to the risk factors in its Form 10-Q for the quarter ended June 30, 2026. It lists market conditions and satisfaction of customary closing conditions as the main risks to completing the deal.